Screener
UroGen Pharma URGN Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $252,590 | $200,455 |
| Liabilities and Shareholders' Deficit | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $39,945 | $27,717 |
| Employee related accrued expenses | 12,253 | 13,516 |
| Current liabilities related to finance leases | 1,411 | 1,274 |
| Current liabilities related to operating leases | 684 | 481 |
| Other current liabilities | 7,622 | 3,430 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's accounts payable?
- UroGen Pharma (URGN) reported accounts payable of $39.95M in Q2 2026.
- How has UroGen Pharma's accounts payable changed year-over-year?
- UroGen Pharma's accounts payable increased by 29.0% year-over-year, from $30.96M to $39.95M.
- What is the long-term trend for UroGen Pharma's accounts payable?
- Over 5 years (2020 to 2025), UroGen Pharma's accounts payable has grown at a 22.6% compound annual growth rate (CAGR), from $10.02M to $27.72M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about UroGen Pharma's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude